论文部分内容阅读
顺铂是治疗头颈部癌肿疗效较好的细胞毒药物之一。常规剂量80—1200C/m~2,缓解率达30—40％。为进一步提高缓解率,本研究旨在探讨应用大剂量顺铂治疗晚期头颈部鳞癌的可能性。 作者所选22例晚期头颈部鳞癌,均经组织学证实。其中以往未经治疗、病变Ⅳ期6例,复发16例。全部病例在治疗前四周内未接受过放疗或化疗。中位年龄53岁(24—65岁),Karnofsky标准评分≥60％,预计生存期≥12周。WBC>3500/μl,血小板>100.000/μl,胆红素<2.0mg％,血肌酐<2mg/dl,24小时肌酐清除率>60ml/min,听觉功能良好。
Cisplatin is one of the best cytotoxic drugs for the treatment of head and neck cancer. The conventional dose of 80-1200C/m~2, the remission rate of 30-40%. In order to further improve the remission rate, the aim of this study was to investigate the possibility of using high-dose cisplatin for the treatment of advanced head and neck squamous cell carcinoma. The authors selected 22 cases of advanced head and neck squamous cell carcinoma, were confirmed by histology. Among them, there were 6 cases with stage IV disease and 16 cases without recurrence. All cases did not receive radiotherapy or chemotherapy within 4 weeks before treatment. The median age was 53 years (24-65 years), the Karnofsky criteria score was ≥ 60%, and the expected survival was ≥ 12 weeks. WBC> 3500/μl, platelet> 100.000/μl, bilirubin <2.0 mg%, serum creatinine <2 mg/dl, 24-hour creatinine clearance> 60 ml/min, good auditory function.